Concepedia

A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes

Seungtaek Lim, Hyun Chang, M.J. Yoon, Yun Hong, H. Kim, Woong Youn Chung, C.-S. Park, Kee‐Hyun Nam, Sang‐Wook Kang, M.K. Kim,

Annals of Oncology · 2013 · 141 citations · 18 references

DOIFull text

Open access

Concepts

References

18

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · The Lancet · 2008 · 3K citations

, , +11

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Arkaitz Carracedo, Li Ma, Julie Teruya‐Feldstein et al. · Journal of Clinical Investigation · 2008 · 1.4K citations · Full text

, , +17

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

Vandana G. Abramson, Andrea B. Troxel, Anoma Nellore et al. · Journal of Clinical Oncology · 2008 · 679 citations · Full text

, , +6

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes et al. · Journal of Clinical Oncology · 2008 · 622 citations · Full text

, , +14